Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects-Reference-Cited by-同舟云学术

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects

Published:2017-11 Issue:11 Volume:39 Page:2243-2259.e5
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Wan Hong,Gumbiner Barry,Joh Tenshang,Riel Tom,Udata Chandrasekhar,Forgues Philippe,Garzone Pamela D.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference45 articles.

1. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation;Brunzell;J Am Coll Cardiol,2008

2. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement;Otvos;Clin Chem,1992

3. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy;Jeyarajah;Clin Lab Med,2006

4. Atherogenic lipoprotein particles in atherosclerosis;Carmena;Circulation,2004

5. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management;Cromwell;J Clin Lipidol,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review;International Journal of Molecular Sciences;2024-07-18

2. A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia;BioMed Research International;2021-10-31

3. PCSK9 E670G (rs505151) Variant and Coronary Artery Disease Risk Among Diabetics;Genetic Testing and Molecular Biomarkers;2021-09-01

4. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk;Vascular Pharmacology;2020-12

5. Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects;Int. Journal of Clinical Pharmacology and Therapeutics;2019-12-01